Cardiologist, NEW YORK UNIVERSITY (INC)
Member of the Healthcare Council
Daniel Fisher, MD, FACC, FACP, is a Cardiologist at NYU Medical Center. He has a private practice in Cardiology and specializes in non-invasive cardiology. Dr. Fisher is board certified in Internal Medicine, Cardiovascular Diseases, and Nuclear Cardiology. He has lectured frequently on such topics as hypertension, lipid management and heart failure. Dr. Fisher has lectured and/or consulted for such companies as Pfizer, Merck, Bristol-Meyers Squibb, and AstraZeneca. (This is me - Update Profile)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Drug-eluting Versus Uncoated Stents
September 19, 2006
NEJM Articles on DES in MI | content.nejm.org
The lead articles from the New England Journal of Medicine 9/14/06 reviewed new data showing benefits when comparing sirolimus-eluting stents to uncoated stents and when comparing paclitaxil eluting stents to uncoated stents.
There was a significant reduction in target-vessel revascularization at one year with the sirolimus-eluting stents compared to uncoated stents.
There was a trend (not statistically significant) toward reduction of serious adverse cardiac events at one year with paclitaxil-eluting stents compared to uncoated stents.
| Study Group Name | No. Members |
|---|---|
| General Cardiologists (US) | 1327 |
| Heart Failure Specialists (US) | 975 |
| Non-Electrophysiologist Cardiologists (US) | 853 |
| Physicians who Treat Hypertension (US) | 792 |
| Physicians who Treat Arrhythmia (US) | 307 |
Daniel Fisher has not participated in any GLG Live Meetings.